Vistin Pharma to Release Q3 and Year-to-Date 2026 Results
News related to:Vistin Pharma ASA · 1 min read
Vistin Pharma ASA will release its third quarter and year-to-date 2026 financial results. The Norwegian pharmaceutical company, headquartered in Oslo, will host a conference call for shareholders and interested parties at 8:30 a.m. Central European Time (CET) on the same day.
The call will be accessible via webcast and audio. Interested participants can join the conference call through the following link: edge.media-server.com/mmc/p/23oqqa3w. Vistin Pharma, known for its sole focus on Metformin Hydrochloride production, will provide an update on its performance and answer any questions from attendees.
Vistin Pharma ASA is a dedicated European producer of Metformin Hydrochloride, a key ingredient in diabetes management. The company’s Metformin is also available as Direct Compressible lubricated granules, making it a preferred supplier to leading pharmaceutical companies. With a well-qualified workforce and a manufacturing facility in Kragerø, Vistin Pharma is well-positioned to meet the demands of its clients.
The conference call will offer an opportunity for investors and stakeholders to gain insights into the company’s financial health and strategic direction. Vistin Pharma’s management will discuss the results and provide a forward-looking outlook for the company.